Abstrakt
Souhrn s komentářem. Citace: Tuttle KR, et al.
Safety of empagliflozin in patients with type 2 diabetes and chronic kidney disease: Pooled analysis of placebo-controlled clinical trials. Diabetes care. 2022 Jun 2; 45(6): 1445-1452.
Souhrn s komentářem. Citace: Tuttle KR, et al.
Safety of empagliflozin in patients with type 2 diabetes and chronic kidney disease: Pooled analysis of placebo-controlled clinical trials. Diabetes care. 2022 Jun 2; 45(6): 1445-1452.